Status:
COMPLETED
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advance...
Eligibility Criteria
Inclusion
- (a) a confirmed diagnosis of uHCC;
- (b) at least one target lesion evaluable by both RECIST 1.1 and mRECIST criteria;
- (c) Child-Pugh Grade A or B.
Exclusion
- (a) previous exposure to other anti-cancer treatments;
- (b) diagnosis of any other primary malignancy;
- (c) significant esophageal varices or observable red wale marks;
- (d) a history of severe cardiac, pulmonary, or renal comorbidities;
- (e) incomplete follow-up records.
Key Trial Info
Start Date :
March 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2023
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT06199297
Start Date
March 2 2021
End Date
July 25 2023
Last Update
January 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wei He
Guangzhou, Guangdong, China, 510000